Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
The primary endpoint was non-inferiority of F OLFIRI + Bev to mF OLFOX6 + BeV in progression-free survival (PFS) The common grade 3 or higher adverse events were leukopenia, neutropenia, diarrhea, febrile neutropenia, peripheral neuropathy, and venous thromboembolism.
